Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

SEOUL,South Korea,May 31,2023 -- Yuhan Corporation (CEO,Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO,Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2,'JIN-A04'. The total contract size is 325 million dollars,and it includes an upfront payment of 1.9 million dollars and milestone payments according to future development,permits,and sales.

From left: Wook-Je Cho,CEO of Yuhan Corporation,and Anna Jo,CEO of J INTS BIO.

JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations,and there is currently no approved oral drug approved to date. Preclinical data of JIN-A04 was recently presented at the 2023 edition of the American Cancer Research Association (AACR) annual meeting in April at Orlando,USA showing strong efficacy in both In-vitro and In-vivo studies.

Yuhan Corporation CEO,Wook-Je Cho said,"We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer drug pipeline in the future."

Anna Jo,CEO of J INTS BIO,said,"JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations." And it can become the most promising Best-in-Class TKI therapy in this field."

Meanwhile,Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022,respectively,and holds a 14.8% stake in the company.